(NYSE: STVN) Stevanato Group Spa's forecast annual revenue growth rate of 3.03% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Stevanato Group Spa's revenue in 2026 is $1,413,178,777.On average, 15 Wall Street analysts forecast STVN's revenue for 2026 to be $392,181,084,120, with the lowest STVN revenue forecast at $374,313,374,496, and the highest STVN revenue forecast at $406,717,525,848. On average, 15 Wall Street analysts forecast STVN's revenue for 2027 to be $428,522,188,440, with the lowest STVN revenue forecast at $406,414,683,312, and the highest STVN revenue forecast at $450,024,008,496.
In 2028, STVN is forecast to generate $469,103,088,264 in revenue, with the lowest revenue forecast at $443,664,315,240 and the highest revenue forecast at $493,330,491,144.